Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk Oxygen therapy 77% Hospitalization 54% Hospitalization time -36% c19early.org/f Pineda et al. Fluvoxamine for COVID-19 EARLY TREATMENT Favors fluvoxamine Favors control
Impact of Fluvoxamine on outpatient treatment of COVID-19 in Honduras
Pineda et al., medRxiv, doi:10.1101/2022.09.27.22280428 (Preprint)
4 Oct 2022    Source   PDF   Share   Tweet
Prospective study of 657 COVID+ outpatients in Honduras, 594 accepting fluvoxamine treatment, showing significantly lower mortality and hospitalization with treatment.
risk of death, 95.6% lower, RR 0.04, p = 0.005, treatment 1 of 594 (0.2%), control 4 of 63 (6.3%), NNT 16, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
risk of oxygen therapy, 76.8% lower, RR 0.23, p < 0.001, treatment 21 of 594 (3.5%), control 12 of 63 (19.0%), NNT 6.4, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
risk of hospitalization, 53.7% lower, RR 0.46, p = 0.04, treatment 30 of 594 (5.1%), control 10 of 63 (15.9%), NNT 9.2, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
hospitalization time, 35.5% higher, relative time 1.36, p = 0.33, treatment 30, control 10.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pineda et al., 4 Oct 2022, prospective, Honduras, preprint, mean age 47.9, 24 authors, study period November 2020 - January 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit